Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep 4;20(1):123.
doi: 10.1186/s12954-023-00813-x.

A Case report of a continuous ambulatory drug delivery (CADD) pump to deliver opioid agonist treatment in an acute care setting

Casey Wigg  1 , Amy Nolen  2 , Lisa Jauhal  3 , Malika Sharma  4
Affiliations
Case Reports

A Case report of a continuous ambulatory drug delivery (CADD) pump to deliver opioid agonist treatment in an acute care setting

Casey Wigg et al. Harm Reduct J. .

Abstract

Background: People with substance use disorder are at risk of complications of drug use and frequent hospitalization and may continue to use substances during admission to acute care. Acute care harm reduction strategies including oral or injectable prescription opioids may aid in care retention and improve health outcomes in this patient population.

Case presentation: A 58-year-old woman with refractory opioid use disorder was admitted to hospital for management of dysphagia secondary to esophageal stricture. She received injectable opioid agonist therapy using a continuous ambulatory drug delivery (CADD) pump in order to facilitate completion of her hospital admission.

Conclusions: The patient successfully received acute medical care with the use of a CADD pump for consistent, patient-controlled opioid administration, with the support of an interdisciplinary team and by respecting the patient's own substance use goals.

Keywords: Harm reduction; Injectable opioid agonist; Retention in care; Substance use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Dong KA, Brouwer J, Johnston C, Hyshka E. Supervised consumption services for acute care hospital patients. CMAJ. 2020;192(18):E476–E479. doi: 10.1503/CMAJ.191365. - DOI - PMC - PubMed
    1. Harm Reduction. https://ontario.cmha.ca/harm-reduction/.Accessed 30 Mar 2023
    1. Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E257. doi: 10.1503/cmaj.170958. - DOI - PMC - PubMed
    1. Ontario Drug Policy Research Network T. On behalf of: changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Published online 2021.
    1. Fairbairn N, Ross J, Trew M, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E1056. doi: 10.1503/cmaj.190344. - DOI - PMC - PubMed

Publication types

Substances